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 Nearly 50% of products tested had contamination issues, in terms of DNA, 
chemical composition or both. 
 
 Pharmaceutical adulteration and undeclared stimulants were detected. 
 
 DNA data highlighted potential allergy concerns, presence of potential toxins and 
animal ingredients, and possible substitution of bird cartilage in place of shark. 
 
 Only 21% of the tested products were able to have at least one ingredient 












Use of herbal medicines and supplements by consumers to prevent or treat disease, 
particularly chronic conditions continues to grow, leading to increased awareness of the 
minimal regulation standards in many countries. Fraudulent, adulterated and contaminated 
herbal and traditional medicines and dietary supplements are a risk to consumer health, 
with adverse effects and events including overdose, drug-herb interactions and 
hospitalisation. The scope of the risk has been difficult to determine, prompting calls for 
new approaches, such as the combination of DNA metabarcoding and mass spectrometry 
used in this study. Here we show that nearly 50% of products tested had contamination 
issues, in terms of DNA, chemical composition or both. Two samples were clear cases of 
pharmaceutical adulteration, including a combination of paracetamol and chlorpheniramine 
in one product and trace amounts of buclizine, a drug no longer in use in Australia, in 
another. Other issues include the undeclared presence of stimulants such as caffeine, 
synephrine or ephedrine. DNA data highlighted potential allergy concerns (nuts, wheat), 
presence of potential toxins (Neem oil) and animal ingredients (reindeer, frog, shrew), and 
possible substitution of bird cartilage in place of shark. Only 21% of the tested products 
were able to have at least one ingredient corroborated by DNA sequencing. This study 
demonstrates that, despite current monitoring approaches, contaminated and adulterated 
products are still reaching the consumer. We suggest that a better solution is stronger pre-
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1.Background: 
Complementary and alternative medicine (CAM) therapies include acupuncture, 
aromatherapy, chiropractic, homeopathy, traditional medicines, herbal and botanical 
medicines and dietary or food supplements. In the United States (USA) and Australia, at 
least 50% of the population uses some form of CAM, often without the knowledge or 
support of their primary practitioner [1]. In spite of increased usage and awareness of CAM, 
there persists the idea among consumers that, as many of these CAM treatments and 
remedies are promoted as ‘natural’, they are also harmless and essentially considering 
‘natural’ to be equivalent to ‘safe’ [2]. These ideals have proven to be false, with reports of 
drug-herb interactions, adverse effects and hospitalisation [3]. An Australian survey on the 
use of complementary and alternative medicines (CAM) in people with Type 2 diabetes 
and/or cardiovascular disease (CVD) found that the average annual expenditure on CAM 
products was A$360 per person [4]. Bailey et al. [5] stated that consumers are moving 
towards a more integrated approach to medicine, with the implied aim to prevent or treat 
disease. In many cases, treatment for such diseases focuses on management rather than 
‘cure’, motivating patients to look for alternative therapies. Cohen, Ernst [6] effectively 











broad range of potential risks posed to such patients with under-reporting of adverse 
effects and drug-herb interactions. Since there is an assumption of safety, patients will often 
not indicate supplement use and need to be directly asked about their herbal supplement 
consumption [6]. 
In addition to safety concerns, there are well-documented quality control problems with 
CAM [7]. Australia currently has some of the most stringent regulations of CAM products 
[8]. Yet, post-market compliance reviews conducted by the Australian Department of Health 
have shown that during the 2016-17 period, 79% of products reviewed breached the current 
regulations, consistent with previous data [9]. Notably, the 2016-17 performance report 
states that the ‘increase in the number of compliance reviews in recent years has not driven 
any improvement in compliance rates’ [9]. These consistent levels of regulatory non-
compliance prompted a review [10], which made several recommendations that have been 
accepted by the Australian Government, including changes to indications for use and 
advertisement of CAM products, and increased post-market surveillance [11] of the 
estimated 11,000 CAM products currently listed on the Australian Register of Therapeutic 
Goods (ARTG).  
Regardless of these proposed changes, there remains an established level of regulatory non-
compliance for CAM products, with a reliance on manufacturers making truthful and 
accurate declarations regarding the composition and manufacturing conditions of their 
products. Assumptions of regulatory compliance contradict data from post-market testing, 
as well as the current literature examining the wider CAM industry [7, 12, 13]. In Australia, 
natural health products were the largest selling over-the-counter products in 2015-16 











worth an estimated US$180 billion by 2020 [15], there is a strong economic motivation to 
‘improve’ products, often with the use of undisclosed ingredients [16]. Previous studies into 
discrepancies between product content and listed ingredients have reported undeclared 
plant materials, ingredient substitution, pharmaceutical adulteration and contamination 
with heavy metals [7, 12, 13].  
It was the aim of this study to investigate these quality control issues in CAM samples 
indicated for cardiovascular health, general wellness/wellbeing, and diet issues, including 
weight loss, gastrointestinal health and metabolism support, using a combination of DNA 
metabarcoding and advanced mass spectrometry techniques (LC-MS). One hundred thirty-
five products purchased in Australian capital cities and online were analysed using this 
multi-faceted biomolecular survey.  
2. Methods: 
2.1 Samples:  
135 CAM products were purchased from pharmacies, health food stores, traditional herbal 
retailers and online in Australian capital cities from 2014 to 2017. The samples existed in a 
variety of formulations including tablets, capsules, gel capsules, tea, chewable tablets and 
gummies, honey, liquids and powders, and were from various origins such as traditional 
Chinese medicine (TCM), Ayurvedic and Western herbal medicines and supplements. The 
products were aliquoted for analysis using sterile techniques and allocated random 
identification numbers. Duplicate samples (for Samples 78, 186 and 253) were two different 
batches of the same product, noted by “1” and “2”. Samples 296 and 307 each consisted of 











2.2 DNA extraction and quantification: 
The DNA extraction procedure followed methods previously described[12, 17]. 
Quantification of the extracted DNA was carried out through polymerase chain reaction 
(PCR) amplification of a plastid gene region using the universal primers trnLgh and a 
mammalian mitochondrial DNA gene region targeting a fragment of the 16S rRNA  (see 
Coghlan et al. [12] for primer details). All PCRs were carried out using an ABI StepONE Plus 
qPCR platform (Applied Biosystems, USA) in a 25 μL volume including: 2 mM MgCl2 (Applied 
Biosystems, USA), 1 × Taq polymerase buffer (Applied Biosystems, USA), 0.4 μM dNTPs 
(Astral Scientific, Australia), 0.1 mg bovine serum albumin (Fisher Biotec, Australia), 0.4 μM 
of each primer, 0.2 μL of AmpliTaq Gold DNA polymerase (Applied Biosystems, USA) and 
SYBR-Green dye. Each sample was amplified using the undiluted extract and two dilution 
points (1:10 and 1:100) to gauge template copy number and identify if PCR inhibitors were 
present. The qPCR conditions were: 50 cycles of 95°C for 30 s, annealing at primer specific 
temperature (Supplementary Table 1) for 30 s, and extension at 72°C for 30 s. 
2.3 Amplicon generation: 
Previously described in [12, 17], fusion primers with unique 6-8 bp multiplex identifier (MID) 
tags were designed for the same plant and mammal primer sets as used for the qPCR above, 
but with the inclusion of a second chloroplast gene region, rbcL (see Coghlan et al. [12] for 
primer details). Fusion tag PCR was carried out using the same cycling conditions, with 
duplicate reactions for each DNA extract. Amplicons were blended into a library pool in 
equimolar amounts, as determined by amplicon concentrations on a Labchip GX Touch HT 
instrument (PerkinElmer, MA, USA). The pooled library was size selected on a Pippin Prep 











primer dimer and cleaned over a QIAquick PCR Purification kit column (Qiagen, USA) 
following manufacturer’s instructions. The final purified library was again quantified on the 
Labchip GX Touch HT to determine the optimal amount of library required for sequencing. 
Amplicon sequencing was carried out on an Illumina MiSeq (Illumina, USA) according to 
manufacturer’s protocols using a 300-cycle V2 kit with a nano flow cell. 
2.4 Bioinformatic analysis: 
The data analysis has been previously described in [12, 17]. The sequencing output files 
were retrieved, filtered and processed using Geneious (v8.1). Samples were deconvoluted 
according to their unique MID tags, with reads that did not match exactly to the primers and 
MID tag sequences at both amplicon ends being filtered out. Reads were dereplicated in 
Geneious and exported for chimera removal in USEARCH using the UCHIME de novo 
method, along with singletons, and uploaded onto a high performance computer (Magnus - 
Pawsey Supercomputing Facility, Perth, Australia) where a BLASTn search was conducted 
against the National Centre for Biotechnology Information (NCBI) GenBank NR database. 
The resultant BLAST files were imported into the program MEtaGenome ANalyzer (MEGAN 
v4.7) for taxonomic analysis. The lowest common ancestor parameters for sequence 
assignments were: min score of 65, top percent of 5, and min support of 1. Taxonomic 
assignments for each sample were evaluated using available databases, and conservative 
estimates of families, genera and species were made.  
2.5 Toxicological analysis: 
Toxicological analysis for contaminants and adulterants such as conventional 











et al. [17]. Samples were crushed, and 50 mg was extracted by two methods, ethanol and 
basic ammonia extractions. Ethanol (EtOH) extraction: 1 mL of absolute EtOH (analytical 
reagent grade; Univar, Sydney AU) with 25 µL of internal standard mixture (see 
Supplementary Table 1) was added to the crushed sample, sonicated and centrifuged. The 
supernatant was evaporated to dryness and reconstituted with 100 µL of absolute EtOH 
before analysis. Basic extraction: 1 mL of glass distilled water and 250 µL of 30% ammonia 
(analytical reagent grade; Chem-Supply, Adelaide AU) were added to the crushed sample 
and vortexed. 5 mL of high purity butyl chloride (BuCl; Honeywell, Adelaide AU) was added, 
and samples further extracted for 15 min using a mechanical roller and then centrifuged. 
The BuCl layer was evaporated to dryness and reconstituted with 100 µL of absolute EtOH 
before analysis.  
Sample extracts were analysed on an Agilent 1200 HPLC-6510 quadrupole time of flight-
mass spectrometer (LC-QTOF-MS) (Agilent Technologies, USA) in positive ESI, auto-MS/MS 
mode with an Acquity BEH C18 column (1.7 m, 3.0 x 50 mm; Waters, USA) and a 
Phenomenex C18 4.0 x 3.0 mm guard cartridge (Phenomenex, USA). Mobile phases A and B 
were acetonitrile and aqueous 0.1% formic acid, respectively, with the following gradient: 0-
0.5 min: 90% B, 0.5-8 min: 90-50% B, 8-10 min: 50-5% B, 10-12 min: 5-0% B, 4-min post-
gradient equilibration at 90% B. Total run time was 12 min with a 0.35 mL/min flow rate, 
increased to 0.4 mL/min for the last 2 min. An injector program was utilised which allowed 
mixing of 2 µL of the ethanolic sample extract with formic acid buffer prior to injection. The 
source temperature was set to 350°C, capillary voltage was 3000 V, and gas flow was 10 
L/min. Skimmer and fragmentor voltages were 65 and 125 V, respectively. The analysis was 











Eclipse Plus C18 column (1.8 m, 4.6 x 50 mm) with C18 guard cartridge (4.0 x 3.0 mm; 
Phenomenex, USA). Sample extracts underwent further analysis on an Agilent 7890 gas 
chromatograph with nitrogen-phosphorous and mass spectrometer detectors (GC-
NPD/MSD). 
Results were processed using MassHunter Qualitative Analysis (vB.07.00) for LC-QTOF-MS 
data, ChemStation for LC (vB.04.01) for LC-UV data and MSD ChemStation (vE.02.00.493) 
software for GC-NPD/MSD data. Peaks were matched against Forensic Science SA’s in-house 
retention time, accurate mass and MS/MS spectral library of approximately 350 
compounds, and a commercial database containing 3,490 MS/MS spectra (Forensic and 
Toxicology Personal Compounds Database and Library, Agilent Technologies).  
Caffeine and paracetamol were quantified using the ethanol extraction described above 
with analysis by LC-UV. Buclizine and chlorpheniramine were quantified using the basic 
extraction with LC-QTOF-MS analysis, as described above. For quantitation of synephrine, 
ephedrine and the ephedrine analogues, samples were extracted with 2 mL of sodium 
acetate buffer (pH 5.7), sonicated and vortexed. The supernatant was passed through a solid 
phase extraction (SPE) cartridge (200 mg/3 mL XTRACT; UCT, USA) and eluted with 
CH2Cl2/propan-2-ol. The eluent was evaporated to dryness and reconstituted with 
methanol. These samples were analysed using an Agilent 1200 HPLC coupled to a Sciex 4000 
QTRAP-MS system (Sciex, USA) in positive ESI multiple reaction monitoring (MRM) mode. 
Mobile phases A and B were methanol and aqueous 0.1% formic acid. Total run time was 9 
min with a 0.80 mL/min flow rate. Source temperature was set to 650°C, ion spray voltage 











reference standards (run in parallel with samples) were used to determine 
adulterant/contaminant concentrations. 
3. Results: 
Figure 1 shows the comparison between the samples listed/not listed on the ARTG, while 
detailed individual sample results can be found in Supplementary Table 2. Overall, 86 
samples (63%) were listed with the TGA and could be found on the ARTG. Of the total 
sample pool, data were obtained for 100 samples (73%), from either DNA or toxicological 
analysis, or both. 
3.1 Genetic analyses: 
Of the 137 samples, 40% (n = 55) were found to contain no amplifiable DNA. Of those 
samples which did contain DNA (n = 82), 51% (n = 42) had additional plant DNA, 30% (n = 
25) contained commonly used ‘filler’ ingredients such as soybean, rice, oat, wheat or 
grasses, 4% (n = 3) had additional animal DNA (DNA from non-domestic animals not listed or 
related to ingredients) and 21% (n = 17) had animal contamination (DNA from domestic 
species such as dog, pig, rat, mouse or cow). Figures 1 B and C show the difference in DNA 
results between ARTG listed and non-listed samples. In the ARTG listed products for which 
DNA data could be generated, 44% (n = 21) had stated ingredients confirmed, 65% 
contained additional plant DNA, 27% contained filler ingredients, 2% contained additional 
animal DNA, and 31% had animal contamination. For the products not listed on the ARTG (n 
= 34), only 24% had stated ingredients confirmed, 32% had additional plant DNA, 35% 












Overall, only 21% (n = 29) of the samples could be considered to have had ingredients 
confirmed by this analysis, with taxonomic assignment corroborating the presence of an 
ingredient listed on the sample packaging. However, some of these samples also contained 
fillers or additional DNA, and not all stated ingredients were identified through DNA 
metabarcoding. 
 3.2 Toxicological data: 
Most of the samples were negative for pharmaceuticals (74%, n = 102). Of those samples 
which did contain pharmaceuticals, 20% (n = 7) were declared on the label or explained by 
the ingredient list, such as caffeine from green tea or synephrine from bitter orange. 19% (n 
= 26) of samples contained caffeine, 14 of which were listed and 12 not listed on the ARTG. 
5% (n = 7) of the samples contained additional unexplained pharmaceuticals, including 
caffeine, synephrine, ephedrine and related alkaloids, paracetamol, chlorpheniramine and 
trace amounts of mycophenolic acid and buclizine (Table 1). Of these seven samples, six 
were listed on the ARTG. 
4. Discussion: 
The data generated in this study continues to highlight a number of concerns with herbal 
CAM products [12, 17]. The large number of products containing undeclared plant 
ingredients indicates either widespread ingredient substitution or that current methods 
used to identify plant ingredients are inadequate. Many products were contaminated with 
animal DNA that cannot be explained based on the ingredient list and may speak to poor 
manufacturing processes. 5% of the samples contained undeclared pharmaceuticals, at least 











4.1 Genetic analysis: 
As found in our previous study [12] and elsewhere [13], the ingredient list for a product 
does not always reflect what is actually contained within that product. Of the 137 samples 
tested in this study, only 21% (n = 29) had at least one of the listed ingredients corroborated 
by DNA barcoding. Furthermore, DNA from plants not listed or related to the product 
ingredients was found in 31% of the samples, making it impossible for consumers and their 
medical professionals to determine exactly what an individual has ingested. This lack of 
regulatory compliance demonstrates serious shortfalls in quality control and/or 
manufacturing processes. DNA from the cashew nut (Anacardium) and the walnut 
(Juglandaceae) families were detected in samples 68 and 319, and 79, respectively, 
presenting possible nut allergy concerns. DNA from Juglans nigra (black walnut) was also 
detected [13] in single-herb products containing ginkgo. Further to this, 18% of samples 
contained filler ingredients, such as Oryza (rice) or Glycine (soybean). The presence of 
undeclared fillers is of particular concern to people with allergies (e.g. celiac disease). 
Unknown ingredients and inaccurate labels increase the potential for adverse and allergic 
reactions because consumers cannot make informed choices [18]. Not only this but in cases 
where an adverse reaction does occur, it will be very difficult to determine the causal agent 
if the ingredient list does not accurately reflect the contents. To highlight this point, sample 
80, indicated for assisting ‘healthy people to maintain cholesterol and triglycerides within 
the normal range’, contained DNA from the Neem tree (Azadirachta indica). Not declared 
on the label as an ingredient, the Neem tree has been widely used in Ayurvedic medicine 
[19] and has many potential bioactive properties. However, Neem oil has also been the 











encephalopathy [20]. Products sold in Australia containing Neem oil for topical application 
need to be labelled with the warnings ‘not to be taken’ and ‘keep out of reach of children’.  
Not only was additional plant DNA detected, but in a small number of samples, additional 
animal DNA or contamination was detected. Contamination from species such as rat, dog, 
goat, pig and other domesticated animals is potentially from manufacturing deficiencies or 
transportation and could be seen as inadvertent [12]. The detection of DNA from non-
domesticated animals is harder to explain. In sample 69, a supplement powder for general 
wellbeing, reindeer DNA (Rangifer tarandus) was detected, while in sample 245, a tea for 
‘slimming’ and ‘detox’, DNA was found from frog (subfamily Rhacophorinae) and the Asian 
Highland Shrew (Suncus montanus). Neither of these products declared animal ingredients, 
and it is possible that this was also inadvertent contamination. However, frog has previously 
been found in herbal products [12] and is a potential deliberate addition for zootherapy 
[21].  
Sample 70 raises questions of ingredient substitution or fraud [21]. Listed only to contain 
shark cartilage (no species information given) and indicated for general wellbeing, as an 
anti-inflammatory and for joint health, the product had animal contamination from rat, dog 
and pig, as well as shark DNA from Galeocerdo cuvier (tiger shark) and Carcharhinus sp., 
indicating that the product was at least partly accurate in its ingredient declaration. 
However, there is also the possibility of ingredient substitution for bird cartilage rather than 
shark, with DNA found from Anatidae sp. and the subfamily Phasianinae. Both bird taxa 
were not reflected on the ingredient list. 
DNA barcoding provides vital information about the composition of a sample, but it does 











40% of the samples in this study. This can be due to various factors, including the nature of 
the product ingredients (e.g. herbal extract), the form of the product itself (e.g. oil capsule) 
or the manufacturing process, where DNA can be totally degraded and therefore unable to 
be detected [22]. Alternatively, it is possible some formulations contain no biological 
material so would never yield a DNA profile. The use of PCR methods for commercial testing 
has also been recently discussed in Newmaster et al. [18], arguing for a transparent system 
and supply chain with well-defined common incidental DNA limit (such as the DNA from 
common domestic species detected in this study). Nevertheless, DNA degradation and its 
loss are key drivers for our suggested multi-tiered approach to pharmacovigilance for CAM 
products [12, 22].  
 4.2 Toxicological analysis: 
Caffeine was the most commonly detected compound in this study, in 19% of samples (n= 
26). The presence of caffeine is chiefly explained by ingredients such as green tea (Camellia 
sinensis), coffee (Coffea canephora) and Yerba Mate (Ilex paraguariensis). Caffeine has a 
long history of use in weight loss and diet products [23, 24], and is one of the most widely 
consumed drugs worldwide [23]. Due to the widespread and generally safe consumption of 
moderate doses of caffeine (up to 400 mg/day) [23], Australian regulations only require a 
product to declare that it contains caffeine [25]. Of the 26 products which were found to 
contain caffeine, the content was declared on the labels of 14, of which 12 were listed on 
the ARTG, fulfilling the labelling requirements. For samples on which this declaration was 
made or when caffeine was expected due to the ingredients, caffeine was not quantified in 
this study. Sample 243 contained a small amount of caffeine (0.55 mg/g) which could not be 











Occurring naturally, Ephedrine and its related alkaloids are produced by plants in the 
Ephedra genus, also known as Mu Huang [26], which has a long history of traditional use. 
Recently, it has become more likely to be abused due to its effectiveness in weight loss and 
performance enhancement, and its stimulant effects. Adverse effects from taking herbal 
medicines which contain ephedrine are well documented and include cardiovascular and 
cerebrovascular complications [27]. This has led to stricter regulations for ephedrine in most 
countries, including a 2004 ban in the USA [28]. Ephedrine taken in combination with other 
stimulant drugs, such as caffeine or synephrine, is another potential risk to consumers [24], 
although, in this study, no products contained this combination.  
Sample 322 was positive for DNA from Ephedra and many other plant families and genera 
including Anthemideae, Astereae, Solanoideae, Acalypheae, Linum, Triticeae and Medicago. 
The sample indicated to ‘balance and support normal male physiology and function, 
enhance stamina and endurance during intense physical activity and maintain the 
production of testosterone levels in the body’, also contained DNA from the family 
Tribuloideae, which includes the only stated ingredient for this product, Tribulus terrestris 
extract. In Australia, Ephedra is restricted to prescription only, unless the total ephedrine 
content is less than 10 mg/kg or 0.001% [25]. With 3 mg/kg or 0.0003% of ephedrine 
content, Sample 322 did not exceed the regulatory limits for ephedrine, but in other 
countries, the detection of Ephedra DNA alone would make this product illegal for sale. 
While the concentration of ephedrine was at trace levels, the larger concern with Sample 
322 is that it is listed on the ARTG, indicating that it claims to comply with safety, quality and 











quality requirements by the contamination of other plant species and no declaration of 
ephedrine content.  
Synephrine is another naturally occurring compound that was detected in this study, in 5% 
(n = 7) of samples. Structurally similar to ephedrine, synephrine occurs in many citrus 
species such as bitter orange (Citrus aurantium), and, like caffeine, has become popular in 
weight loss and diet assistance products. In the case of sample 44, none of the plants listed 
or found in the DNA screen (see Supplementary Table 2) are from genera known to contain 
synephrine and the levels that would be consumed in recommended doses of Sample 
44 (6.2 mg) would be a threshold dose for pharmacological activity only. While the presence 
of the compound without the associated botanicals indicates was likely to have been added 
exogenously. Defining this addition as either contamination or adulteration with near-active 
concentrations is however difficult. 
Sample 296B contained paracetamol and chlorpheniramine (Table 1), suggesting deliberate 
adulteration of this product. Paracetamol is a common over-the-counter analgesic, 
however, dosage information must be followed, as overdose will result in hepatotoxicity. In 
cold and flu medication, paracetamol is often combined with an antihistamine such as 
chlorpheniramine. While chlorpheniramine is an over-the-counter medicine in Australia, the 
packet must carry a sedation warning, as impairment occurs even at low doses [29]. As a 
first-generation antihistamine, the most common side effects are drowsiness, sedation, 
fatigue, coordination disturbances and impaired memory [30]. Stated to be ‘suitable for 
people with high cholesterol levels, skin problems, simple obesity and for improvement of 
general health’, there appears to be no obvious reason for Sample 296B to contain this 











chlorpheniramine (0.32 and 0.0034 mg, respectively) would be at or below the threshold for 
pharmacological activity, yet the presence of these synthetic drugs, even at sub-therapeutic 
amounts, again raises concerns about quality and manufacturing conditions.  
Trace amounts of buclizine and mycophenolic acid were detected in Samples 86 and 162, 
respectively, and were most likely contaminants from manufacturing. Both products were 
listed on the ARTG, and the presence of these drugs implies failings in manufacturing 
standards. Buclizine is a first-generation antihistamine that has been superseded by more 
successful drugs of its class. To the best of the authors’ knowledge, buclizine is not currently 
used in Australia, Europe or the USA, and is only available in the UK in combination with 
paracetamol and codeine (brand name Migraleve Pink) for treatment of migraine. The 
detection of trace amounts (0.2 g/g) of this drug in Sample 86, a product purportedly 
manufactured in Australia and marketed for ‘increased energy, stress resistance, improved 
immunity, sexual function and healthy heart’ is of some concern. Mycophenolic acid, 
detected in trace amounts (below LOQ and not quantified) in Sample 162, is a prescription-
only immunosuppressant medicine. Once again, this drug should not have been found in 
any concentration in this product.  
The use of routine screening methods did limit the findings of this study. Samples were only 
analysed using positive ionisation and only therapeutically relevant LOQ values are 
achieved. Despite these limited restrictions from the use of routine methods in this study, if 
safety and quality control measures of CAM products were sufficient, this study would 
report zero cases of undeclared pharmaceuticals in the ARTG listed products. Instead, clear 
cases of adulteration and the presence of pharmaceuticals of indeterminate (and often 












Of the samples analysed in this study, 63% were listed on the ARTG (n = 86), meaning that 
these products have been assessed for safety and quality under current regulation, and are 
only allowed to contain approved ingredients [25]. Those samples which were not listed 
with the TGA were purchased online, exempt from regulation (e.g. some homoeopathic 
products) or should not have been able to be purchased on the Australian market. The fact 
that the authors could purchase these products suggests a failure in regulatory control, 
demonstrating a clear need to strengthen the regulation of these products to improve 
consumer safety. While a worthy effort, increasing post-market testing will not keep non-
compliant and potentially dangerous products from being sold in the first place. This study 
has shown that contaminated and adulterated products are not minor, niche-market 
remedies, but are sold in some of the biggest health food stores and pharmacies in 
Australia. Pre-market evaluation using the methods described here and in our previous 
studies [12, 17] would provide an audit toolkit that could better prevent contaminated and 
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Figure 1: A) Compassion between the categories of adulteration, contamination 
undeclared ingredients of the samples listed/ not listed on the ARTG. B and C) The DNA 
results from the samples listed (B, green) and not listed (C, black) on the ARTG which 
contained DNA. Percentage of samples in each category is shown.   *DNA from plants or 
animals listed as main ingredients found. Samples may still contain fillers or additional DNA.
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